Main Article Content
Background and Aims: Lung cancer includes small cell lung cancer and non-small cell lung cancer (NSCLCs) types. NSCLCs are investigated for various mutations, which is available can be treated with targeted new molecular therapies. The aim of this study was to evaluate the expression of SKOR2 gene, disease severity, and evaluation of NSCLC and its subtypes of cancer patients among patients with lung cancer in Tehran hospitals using Real-Time PCR.
Materials and Methods: A total of 35 clinical samples were collected from patients with NSCLC-derived lung cancer from three hospitals in Tehran. The range of patients varied from 37 to 80 years. The disease grade ranges in the patients in this study were varied and 22 different grades were observed. In order to evaluate the SKOR2 gene after extraction of RNA and cDNA synthesis, the gene expression was evaluated using Real-Time PCR.
Results: Of the 22 observed grades, the highest grade IIIa grade was observed in 6 patients (17.1%). 74% of adenocarcinoma cases were in T-categories of lung cancer and 25% of patients were in grade IIIa. Patients with T3 stage included 4 samples, 2 of which were adenocarcinoma and 2 were SCC and their age ranged from 55 to 62 years old. Three patients were in the T1 category, and 100% of them had adenocarcinoma. The results showed that expression of SKOR2 5.47 fold in lung cancer patients with NSCLC was more than normal patients.
Conclusion: According to the results, expression of the SKOR2 gene in the tissues of individuals with lung cancer was increased compared to normal individuals. The expression of this gene in patient suggests the possibility of involvement of this agent in the progression of the disease. According to the results, it is recommended to use an evaluation of the expression of other biomarkers in lung cancer to help with this and to increase the accuracy of screening tests for lung cancer.
Jemal A, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008;100(23):1672-94.
Alberg AJ, et al. Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e1S-e29S.
Travis WD, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.J Thorac Oncol. 2011;6(2):244-85.
Arndt S, et al. Cloning and functional characterization of a new Ski homolog, Fussel-18, specifically expressed in neuronal tissues. Lab Invest. 2005;85(11): 1330-41.
Mizuhara E, et al. Corl1, a novel neuronal lineage-specific transcriptional corepressor for the homeodomain transcription factor Lbx1. J Biol Chem. 2005;280(5):3645-55.
Arndt S, et al. Fussel-15, a novel Ski/Sno homolog protein, antagonizes BMP signaling. Mol Cell Neurosci. 2007;34(4): 603-11.
Jagla K, et al. Mouse Lbx1 and human LBX1 define a novel mammalian homeobox gene family related to the Drosophila lady bird genes. Mech Dev. 1995;53(3):345-56.
Wu JW, et al. Structural mechanism of Smad4 recognition by the nuclear oncoprotein Ski: insights on the Ski-mediated repression of TGF-beta signaling. Cell, 2002;111(3):357-67.
Deheuninck J, K Luo K. Ski and SnoN, potent negative regulators of TGF-beta signaling. Cell Res. 2009;19(1):47-57.
Deheuninck J, K Luo K. Ski and SnoN, potent negative regulators of TGF-β signaling. Cell Research. 2009;19(1):47-57.
Johnson DH, Schiller JH, Bunn PA. Recent clinical advances in lung cancer management. Journal of Clinical Oncology. 2014;10(32):973-982.
Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
Shepherd FA, et al. The International Association for the Study of Lung Cancer lung cancer staging project: Proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol. 2007;2(12):1067-77.
Govindan R, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006; 24(28):4539-44.
Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 2013;31(8):992-1001.
Thomas CM, Sweep CG. Serum tumor markers: past, state of the art and future. Int J Biol Markers. 2001;16(2):73-86.
Duffy MJ. Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci. 2001; 38(3):225-62.
Buccheri G, D Ferrigno D. Lung tumor markers in oncology practice: A study of TPA and CA1. British Journal of Cancer. 2002;87(10):1112-1118.
Jacobson DR, CL Fishman CL, Mills NE. Molecular genetic tumor markers in the early diagnosis and screening of non-small-cell lung cancer. Ann Oncol. 1995;6 Suppl 3:S3-8.